Notes
including any used to specifically treat COVID-19 (including any medicines used off-label), and any medicines taken for the long-term management of pre-existing conditions.
including patient information (including age and gender); whether COVID-19 infection was confirmed through testing, or was based on clinical symptoms; a description of the adverse reactions; the name of medicine (i.e. active ingredient + brand name) suspected to have caused the adverse reactions; the dose and duration of treatment with the medicine; and the batch number of the medicine.
References
1. European Medicines Agency. Reporting suspected side effects of medicines in patients with COVID-19. Internet Document : 24 Apr 2020. Available from: URL: https://www.ema.europa.eu/en/news/reporting-suspected-side-effects-medicines-patients-covid-19
2. European Medicines Agency. COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine. Internet Document : [2 pages], 23 Apr 2020. Available from: URL: https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine
3. Medicines and Healthcare products Regulatory Agency (UK). Coronavirus (COVID-19): latest guidance for medicines safety. Drug Safety Update 13: 2-4, No. 9, Apr 2020. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881559/April-2020-DSU-PDF.pdf
Rights and permissions
About this article
Cite this article
Evaluation of potential therapies for COVID-19 global pandemic. Reactions Weekly 1803, 2 (2020). https://doi.org/10.1007/s40278-020-78196-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-78196-3